We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-21.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.63B
AUM Growth
-$1.11B
Cap. Flow
-$123M
Cap. Flow %
-4.66%
Top 10 Hldgs %
51.48%
Holding
146
New
29
Increased
20
Reduced
29
Closed
45

Top Buys

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$123M
2
AMRN
Amarin Corp
AMRN
+$77.8M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$47.7M
4
ALLO icon
Allogene Therapeutics
ALLO
+$41M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$39M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$72M
2
CORI
Corium International, Inc.
CORI
+$60.5M
3
ECYT
Endocyte, Inc. Common Stock
ECYT
+$43.4M
4
ISRG icon
Intuitive Surgical
ISRG
+$41.6M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$37.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.94%
2 Miscellaneous 1.24%
3 Consumer Staples 0.68%
4 Financials 0.08%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$15.2B
$315M 12%
4,608,554
-168,700
-4% -$16.2M
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
$223M 8.48%
5,425,726
+276,816
+5% +$10.4M
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$192M 7.3%
20,724,424
+30,000
+0.1% +$330K
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
$138M 5.26%
3,790,216
-17,416
-0.5% -$713K
IOVA icon
5
Iovance Biotherapeutics
IOVA
$4.24B
$108M 4.12%
12,241,111
+4,950,912
+68% +$47.7M
SLDB icon
6
Solid Biosciences
SLDB
$897M
$105M 4.01%
+261,815
New +$123M
CRNX
7
DELISTED
Crinetics Pharmaceuticals
CRNX
$77.6M 2.95%
2,587,953
– –
QTNT
8
DELISTED
Quotient Limited Ordinary Shares
QTNT
$66M 2.51%
269,726
+50,000
+23% +$13.1M
AMRN
9
Amarin Corp
AMRN
$294M
$64.6M 2.46%
243,780
+213,270
+699% +$77.8M
ASND icon
10
Ascendis Pharma A/S
ASND
$15.8B
$63M 2.4%
1,052,647
-20,000
-2% -$1.26M
ARNA
11
DELISTED
Arena Pharmaceuticals Inc
ARNA
$55.6M 2.12%
1,430,171
+63,193
+5% +$2.48M
ARGX icon
12
argenx
ARGX
$61.3B
$53.9M 2.05%
560,941
– –
MYOK
13
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$53.5M 2.04%
1,075,216
-13,953
-1% -$768K
MMSI icon
14
Merit Medical Systems
MMSI
$5.15B
$52.2M 1.99%
949,198
-45,000
-5% -$2.68M
TVTX icon
15
Travere Therapeutics
TVTX
$5.89B
$49.8M 1.89%
3,342,038
+129,167
+4% +$3.21M
MGTX icon
16
MeiraGTx Holdings
MGTX
$1.23B
$45.3M 1.73%
4,703,398
– –
CTMX icon
17
CytomX Therapeutics
CTMX
$586M
$43.6M 1.66%
2,911,715
+250,000
+9% +$3.71M
BPMC
18
DELISTED
Blueprint Medicines
BPMC
$43.5M 1.65%
857,326
-83,821
-9% -$5.09M
ALLO icon
19
Allogene Therapeutics
ALLO
$594M
$41.6M 1.58%
+1,543,790
New +$41M
LJPC
20
DELISTED
La Jolla Pharmaceutical Company
LJPC
$41M 1.56%
4,313,611
– –
XLRN
21
DELISTED
Acceleron Pharma
XLRN
$39.9M 1.52%
905,017
-623,188
-41% -$31.1M
ALBO
22
DELISTED
Albireo Pharma Inc
ALBO
$39.5M 1.5%
1,704,330
– –
VBIV
23
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$38.3M 1.46%
798,385
+476,190
+148% +$26.1M
ATNX
24
DELISTED
Athenex, Inc. Common Stock
ATNX
$32.5M 1.24%
254,801
+111,325
+78% +$28.3M
MNTA
25
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$31.1M 1.18%
2,825,000
+2,800,511
+11,436% +$39M
1
2 3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2018 Portfolio in Review

As of Q4 2018, Perceptive Advisors held 146 positions worth $2.63B, down 30% from $3.74B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors withdrew a net $123M in Q4 2018, closing 45 positions and reducing 29 holdings. Its most notable exit was Corium International, Inc., an estimated $60.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 93% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in Solid Biosciences worth $105M.

  • Perceptive Advisors's largest Q4 2018 buy was Solid Biosciences: 261,815 shares worth $105M.
  • Perceptive Advisors added most to Amarin Corp in Q4 2018, an estimated $77.8M increase.
  • Perceptive Advisors's biggest Q4 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $72M.
  • Perceptive Advisors fully exited Corium International, Inc. in Q4 2018, selling an estimated $60.5M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $2.63B portfolio in Q4 2018.
  • Perceptive Advisors opened 29 new positions and closed 45 in Q4 2018.
  • Perceptive Advisors's portfolio value fell 30% quarter-over-quarter to $2.63B.

Based on Perceptive Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.